下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>
多维分析
公司估值 资金追踪 卖空分析
富途牛牛 > 行情 > MRNA Moderna > 关键指标
MRNA Moderna
123.640
-0.680-0.55%
盘前价
122.340
-1.3-1.05%
显示同比
不显示
隐藏空行
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
-50.95% 141.9328 -85.39% 171.4141 -94.85% 128.4781 -94.85% 128.4781
Receivable Turnover(T)
57.97% 9.4604 450.44% 6.8616 1891.42% 7.7521 1891.42% 7.7521
Inventory Turnover(T)
114.77% 3.1763 594.57% 2.8251 1963.65% 3.5186 1963.65% 3.5186
Fixed Assets Turnover(T)
87.08% 19.0137 330.09% 22.6815 2363.98% 20.0397 2363.98% 20.0397
Total Asset Rate(T)
67.3% 1.0562 298.97% 1.0884 1702.06% 1.1083 1702.06% 1.1083
ROIC
62.36% 107.068% 552.07% 131.218% 463.74% 135.272% 463.74% 135.272%
ROE
57.2% 113.856% 541.36% 139.990% 465.27% 146.076% 465.27% 146.076%
ROA
87.17% 66.618% 796.64% 72.640% 555.52% 76.249% 555.52% 76.249%
FCF to Sales
-71.78% 41.353% -76.11% 59.413% -89.47% 75.192% -89.47% 75.192%
FCF to Net Income
-74.77% 65.564% -89.37% 89.022% -- 109.294% -- 109.294%
Efficiency Ratios
ROA 5 Year Average
-- -- -- -- 84.18% -3.478% -- --
Profitability Ratios TTM
Gross Margin
-3.47% 81.727% -6.34% 84.311% -12.22% 85.245% -12.22% 85.245%
Operating Margin
13.98% 70.194% 135.45% 74.121% 126.96% 74.966% 126.96% 74.966%
Net Margin
11.88% 63.072% 124.74% 66.740% 125.28% 68.798% 125.28% 68.798%
EBITDA Margin
13.08% 0.7175% 120.27% 0.7555% 129.78% 0.7631% 129.78% 0.7631%
R & D Expense Ratio
-64.84% 10.920% -88.11% 9.780% -97.75% 11.230% -97.75% 11.230%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Financial Health Ratios
Long-Term Debt to Equity Ratio
-37.33% 4.048% -28.82% 4.340% -38.42% 4.984% -38.42% 4.984%
Total Assets to Common Equity
-39.9% 144.804% -51.11% 161.693% -39.11% 174.401% -39.11% 174.401%
Debt to Asset Ratio
-45.17% 4.932% -9.03% 5.546% -19.98% 6.476% -19.98% 6.476%
Current Ratio
60.46% 1.991 27.65% 1.7699 22.69% 1.7606 22.69% 1.7606
Quick Ratio
38.54% 1.5768 12.34% 1.4591 12.03% 1.5363 12.03% 1.5363
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- 2598.1% 425.080% -- --
Revenue CAGR(5Y)
-- -- -- -- -- 180.832% -- --
FCF 1 Year Growth
-- -- -- -- -- 580.574% -- --
FCF CAGR(5Y)
-- -- -- -- -- 230.951% -- --
Currency Unit
美元美元美元美元

FY:Financial Year 年度报告,相当于上市公司向SEC披露的10-K文件。

Q:Quarter 季度报告,相当于上市公司向SEC披露的10-Q文件,其中Q1、Q2、Q3、Q4为单季报,跨度为3个月;Q6、Q9为累计季报,Q6为6个月,Q9为9个月。

环比数据来源于季报,环比 = (本期 - 上期)/上期 * 100%

公司概况 更多
Moderna公司致力于基于信使核糖核酸的变革性药物的开发。其产品线包括以下形式:预防性疫苗、癌症疫苗、肿瘤内免疫肿瘤学、局部再生疗法、全身分泌疗法和全身细胞内疗法。该公司由Noubar B.Afeyan、Robert S.Langer,Jr.、Derrick J.Rose和Kenneth R.Chien于2010年创立,总部设在马萨诸塞州剑桥市。
CEO: --
所属市场: 纳斯达克
上市日期: 2018/12/07
富途热股榜
美股港股沪深
交易热度搜索热度资讯热度
名称代码最新价涨跌幅

加载中...

自选
回到顶部